Introducing the Invisishield Technology Platform
Our novel, proprietary technology platform is designed to create pathogen-specific biomedicines for the prevention of airborne diseases, including COVID-19, flu, RSV, and more. This platform consists of 1) a pathogen-engaging component that specifically recognizes and binds to disease-causing viruses, 2) a killing component that activates complement and "kills" the viruses, and 3) our proprietary nasal retention technology that increases durability of the agent on human mucosal surfaces, providing an extended period of protection.
Our Approach
At InvisiShield Technologies, our team of scientists is designing products that offer protection against a wide range of respiratory viruses, both known and emerging. We adopt a multiprong approach to go after different types of respiratory viral diseases, including COVID-19, RSV and flu. Our science is built on a foundation of scientific expertise, with groundbreaking concepts that set us apart from conventional approaches:
Addressing all current and potential future SARS-CoV-2 variants
Our products are designed to target the commonalities of the given virus type. These shared viral characteristics tend to stay the same even as variants continuously evolve. By identifying and targeting these common traits, InvisiShield's preventive sprays can effectively neutralize both current and potential future variants.
Enhancing protection with nasal-retention technology
InvisiShield's unique nasal-retention technology allows our preventive sprays to remain in the nasal cavity for an extended period, ensuring longer protection against respiratory viruses. In pre-clinical studies, our lead candidate, IS101, provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested. This prolonged action propelled by the nasal retention technology keeps the initial dose low reducing potential toxicity and cost and will allow for a once-a-day dosing schedule.
Initiating “capture and kill” upon engagement with viruses
Once applied, InvisiShield's nasal spray effectively "captures" viral particles in the human nasal cavity. Simultaneously, upon activation, the spray triggers the complement system and "kills" the viruses in one go, eliminating invading viruses before they can infect healthy cells. This property could also diminish forward transmission of the virus to other hosts.
By combining these transformative innovations, InvisiShield is poised to revolutionize strategies to protect us from respiratory virus infection. We are exploring combining sprays for SARS-CoV-2, flu, and RSV in a single cocktail that could prove particularly useful for elderly and immunocompromised individuals who bear particularly high risk of negative outcomes from these viruses.
Product Candidates
InvisiShield’s Intranasal COVID-19 Preventive Spray - IS101
Our lead product, IS101, is an intranasal COVID-19 preventive spray that provides daily protection on the nasal cavity surface, the principal portal of viral entry.
1
Once sprayed into the nostrils, IS101 forms a protective layer of “invisible shield”
2
COVID-19 variants enter the upper respiratory tract
3
IS101 “captures and kills” the SARS-CoV-2 viruses
4
IS101 protects against SARS-Cov-2 for extended hours
.png)
IS101 Prevents Infection by All Common SARS-CoV-2 Variants
In a cell-based assay model of SARS-CoV-2 infection, even at low concentrations, IS101 is still able to prevent infection by all common SARS-CoV-2 variants*.
*Based on studies performed using in vitro models with viruses pseudotyped with SARS-CoV-2 variant spike.
InvisiShield Sprays Prevent Viral Infections in vivo
Building on the successful concept of IS101, we are expanding our product pipeline to cover more respiratory diseases.
Our proprietary technology platform can also be applied to other respiratory viruses, including Type A and B influenza and RSV. Our long-term goal is to create bivalent or trivalent preventative sprays. Building on the successful concept of IS101, we are expanding our product pipeline to address more respiratory diseases, including bivalent or trivalent sprays against multiple viruses at the same time.